Prostate cancer has become an alarming health issue, particularly among African men, who are increasingly found to be at higher risk compared to men of other ethnicities. Various studies point towards genetic factors playing a significant role in this elevated risk, coupled with inadequate
Recent research from Weill Cornell Medicine has unveiled a promising preclinical discovery that could significantly enhance the effectiveness of cancer immunotherapy for B-cell non-Hodgkin lymphomas (B-NHL). The study focuses on the use of EZ## inhibitors, an emerging class of anticancer drugs, in
The field of organic chemistry has witnessed a significant breakthrough with the development of a highly (E)-selective Weinreb amide-type Horner–Wadsworth–Emmons (HWE) reaction. This advancement was achieved by a team from the Department of Applied Chemistry at Tokyo University of Science (TUS) in
In a remarkable breakthrough in breast cancer treatment, a novel cell-based immunotherapy developed by Dr. Gary Koski from Kent State University and Dr. Brian J. Czerniecki from the Moffitt Cancer Center has been recently accepted for publication in JAMA Oncology. This innovative approach harnesses
Scientists have long sought to understand the various factors that contribute to the prevalence of cancer, and recent research has shed light on a surprising potential culprit: Escherichia coli (E. coli). A study conducted by researchers from the Wellcome Sanger Institute and the University of
For lymphoma patients, particularly those facing relapsed or refractory large B cell lymphoma (LBCL), CAR T cell therapy represents a beacon of hope. This promising treatment, epitomized by Breyanzi (lisocabtagene maraleucel), offers a new avenue for those who have exhausted conventional treatment
